Clene Announces Publication Of Phase 2 CNM-Au8 Clinical Data For The Treatment Of ALS In LANCET's eClinicalMedicine
Portfolio Pulse from Happy Mohamed
Clene Inc. announces the publication of Phase 2 clinical data for CNM-Au8, a treatment for ALS, in The Lancet's eClinicalMedicine. The data includes results from the RESCUE-ALS trial and its open-label extension, showing a clear survival signal and delayed clinical worsening morbidity events. Clene plans to report long-term follow-up data and meet with the FDA in Q3.
June 26, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clene Inc. published positive Phase 2 clinical data for CNM-Au8, a treatment for ALS, in The Lancet's eClinicalMedicine. The data shows promising results, and Clene plans to report long-term follow-up data and meet with the FDA in Q3.
The publication of positive Phase 2 clinical data for CNM-Au8 in a reputable journal like The Lancet's eClinicalMedicine is a significant milestone for Clene Inc. This news is likely to have a positive short-term impact on the company's stock price, as it demonstrates progress in the development of the treatment and increases the likelihood of regulatory approval. The planned long-term follow-up data and FDA meeting in Q3 further support this positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100